Q1: 2026-05-07 Earnings Summary
EPS of -$0.59 misses by $0.49
|
Revenue of
$2.41M
(-91.12% Y/Y)
misses by $33.17M
Zymeworks Inc. (ZYME) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDT
Company Participants
Shrinal Inamdar - VP of Investor Relations
Kenneth Galbraith - Chairman of the Board, CEO & President
Kristin Stafford - Executive VP & CFO
Paul Moore - Chief Scientific Officer
Sabeen Mekan - SVP & Chief Medical Officer
Adam Schayowitz - Executive VP and Head of Research & Development
Conference Call Participants
Eva Fortea-Verdejo - Wells Fargo Securities, LLC, Research Division
Yue-Wen Zhu - LifeSci Capital, LLC, Research Division
Jonathan Miller - Evercore ISI Institutional Equities, Research Division
Yigal Nochomovitz - Citigroup Inc. Exchange Research
Mayank Mamtani - B. Riley Securities, Inc., Research Division
Reni Benjamin - Citizens JMP Securities, LLC, Research Division
Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division
Yaron Werber - TD Cowen, Research Division
Lut Ming Cheng - JPMorgan Chase & Co, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to Zymeworks First Quarter 2026 Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Shrinal Inamdar, VP of Investor Relations. Your line is open.
Shrinal Inamdar
VP of Investor Relations
Thank you, operator. Good afternoon, everyone, and thank you for joining our first quarter 2026 results conference call. As usual, I'd like to remind you that we'll be making a number of forward-looking statements during this call, including, without limitation, those forward-looking statements identified in our slides and the accompanying oral commentary. These forward-looking statements are based upon our current expectations and various assumptions and are subject to the risks and uncertainties, including those associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as filed with the SEC.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。